Hendrik‐Tobias Arkenau

Encorafenib, Binimetinib, and Cetuximab in <i>BRAF</i> V600E–Mutated Colorectal Cancer

Scott Kopetz, Axel Grothey, Rona Yaeger et al. · New England Journal of Medicine · 2019 · 1.5K citations · Full text

Medicine, Oncology, Pharmacology +17

Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor study

Luc Dirix, István Takács, Guy Jérusalem et al. · Breast Cancer Research and Treatment · 2017 · 756 citations · Full text

Medicine, Oncology, Pharmacology +17

Phase III Study of Capecitabine Plus Oxaliplatin Compared With Fluorouracil and Leucovorin Plus Oxaliplatin in Metastatic Colorectal Cancer: A Final Report of the AIO Colorectal Study Group

Rainer Porschen, Hendrik‐Tobias Arkenau, S. Kubicka et al. · Journal of Clinical Oncology · 2007 · 279 citations · Full text

Medicine, Oncology, Pharmacotherapy +16

Phase I/II study of GSK2118436, a selective inhibitor of oncogenic mutant BRAF kinase, in patients with metastatic melanoma and other solid tumors.

Richard Kefford, Hendrik‐Tobias Arkenau, Michael P. Brown et al. · Journal of Clinical Oncology · 2010 · 274 citations

Medicine, Oncology, Pharmacology +17

Tisotumab vedotin in patients with advanced or metastatic solid tumours (InnovaTV 201): a first-in-human, multicentre, phase 1–2 trial

Johann S. de Bono, Nicole Concin, David S. Hong et al. · The Lancet Oncology · 2019 · 230 citations · Full text

Medicine, Immunology, Oncology +11